The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder

National Taiwan University Hospital24 enrolled

Overview

Phase advance of HRV will be anticipated in agomelatine group. It is anticipated that both agomelatine and floxentine will increase HRV at the end of the treatment.

Phase advance of HRV will be anticipated in agomelatine group. It is anticipated that both agomelatine and floxentine will have equal efficacy in improvement of depressive symptoms and increasement of HRV at the end of the treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE

Enrollment

Conditions

Depressive Disorder, Major

Interventions

AgomelatineDRUG

FluoxentineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Asian patients * Male or female * 18 to 65 years outpatients * DSM-IV-TR criteria for Major Depressive Disorder Exclusion Criteria: * Patients with cardiac conditions and other physical conditions contraindicated for drug study * Shift worker * Patients known to be non-responders to fluoxetine treatment * Pregnancy, or breastfeeding

Locations (1)

National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

the Pittsburgh Sleep Quality Index

the Leeds Sleep Evaluation Questionnaire

Secondary Outcomes

heart rate variability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.